Media headlines about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.7616400211175 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Canaccord Genuity Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $9.00 Price Target (americanbankingnews.com)
- Zynerba Pharmaceuticals, Inc. (ZYNE) Forecasted to Post FY2019 Earnings of ($1.59) Per Share (americanbankingnews.com)
- Jefferies Group LLC Downgrades Zynerba Pharmaceuticals, Inc. (ZYNE) to Hold (americanbankingnews.com)
- Zynerba Pharmaceuticals, Inc. (ZYNE) Given a $7.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- Zynerba Pharmaceuticals Inc. (ZYNE) Has Tumbled To A New Low On Study Results (rttnews.com)
Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 1.11% during trading on Friday, hitting $6.25. The company had a trading volume of 424,137 shares. The stock’s market capitalization is $82.86 million. The company’s 50 day moving average price is $14.21 and its 200-day moving average price is $18.65. Zynerba Pharmaceuticals has a 1-year low of $5.42 and a 1-year high of $25.95.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.04. On average, analysts expect that Zynerba Pharmaceuticals will post ($2.45) EPS for the current year.
A number of analysts have recently commented on ZYNE shares. Cantor Fitzgerald reissued a “buy” rating and set a $28.00 price target on shares of Zynerba Pharmaceuticals in a research note on Tuesday, May 9th. Roth Capital set a $30.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, May 13th. Canaccord Genuity set a $35.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, May 13th. Maxim Group set a $32.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, June 26th. Finally, Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $12.67.
WARNING: This report was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/20/zynerba-pharmaceuticals-zyne-earns-media-sentiment-score-of-0-10.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
